FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2602448426> ?p ?o ?g. }

• W2602448426 endingPage "29268" @default.
• W2602448426 startingPage "29258" @default.
• W2602448426 abstract "// Hong Tao Hu 1 , Jun Peng Luo 1 , Hai-Liang Li 1 , Chen Yang Guo 1 , Quan Jun Yao 1 , Xiang Geng 1 , Li Jiang 1 1 Department of Radiology and Research Institute of Radiology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan Province 450003, P. R. China Correspondence to: Hai-Liang Li, email: irlihailiang@163.com Keywords: hepatocellular carcinoma, portal vein tumor thrombus, transarterial chemoembolization, 125 iodine implantation, computed tomography-guided Received: October 11, 2016      Accepted: February 14, 2017      Published: March 23, 2017 ABSTRACT We conducted a retrospective study to evaluate the safety and efficacy of transarterial chemoembolization (TACE) combined with computed tomography-guided 125 iodine implantation (TACE- 125 iodine) in hepatocellular carcinoma (HCC) patients with type B portal vein tumor thrombus (PVTT). From medical records, we determined that 50 patients who received 125 iodine implantation 4-7 days after the first TACE session showed better survival than 50 patients who received only TACE (median survival, 13.1 vs. 6.0 months; P <0.01). Moreover, the PVTT control rate was higher in the TACE- 125 iodine than TACE alone group (78% vs. 18%; P <0.01). Multivariate analysis demonstrated that the TACE- 125 iodine procedure was an independent prognostic factor for overall survival. We also observed that bilirubin levels were increased at 4 weeks, indicating that 125 iodine seeding in the PVTT beneficially impacted the small bile duct, which is proximal to the portal vein. No severe adverse events were observed in patients that received 125 iodine seed implantation, and the mild adverse events were successfully treated. This study shows that TACE- 125 iodine therapy enhances patient survival with minimal adverse events. It is also more affordable than sorafenib, which is currently the recommended therapy for advanced HCC patients with PVTT." @default.
• W2602448426 created "2017-04-07" @default.
• W2602448426 creator A5000083222 @default.
• W2602448426 creator A5000731922 @default.
• W2602448426 creator A5012001115 @default.
• W2602448426 creator A5039313839 @default.
• W2602448426 creator A5046632194 @default.
• W2602448426 creator A5066890510 @default.
• W2602448426 creator A5091599854 @default.
• W2602448426 date "2017-03-23" @default.
• W2602448426 modified "2023-10-03" @default.
• W2602448426 title "Transarterial chemoembolization combined with computed tomography-guided 125iodine implantation enhances survival in hepatocellular carcinoma patients with portal vein tumor thrombus" @default.
• W2602448426 cites W1012017157 @default.
• W2602448426 cites W151439609 @default.
• W2602448426 cites W1531185157 @default.
• W2602448426 cites W1870806980 @default.
• W2602448426 cites W1971837077 @default.
• W2602448426 cites W1978756427 @default.
• W2602448426 cites W1994193851 @default.
• W2602448426 cites W2010384597 @default.
• W2602448426 cites W2029286476 @default.
• W2602448426 cites W2047554241 @default.
• W2602448426 cites W2049578982 @default.
• W2602448426 cites W2057378223 @default.
• W2602448426 cites W2067095091 @default.
• W2602448426 cites W2071250178 @default.
• W2602448426 cites W2073718949 @default.
• W2602448426 cites W2079586464 @default.
• W2602448426 cites W2082560693 @default.
• W2602448426 cites W2083976956 @default.
• W2602448426 cites W2138003597 @default.
• W2602448426 cites W2143392238 @default.
• W2602448426 cites W2149472625 @default.
• W2602448426 cites W2158150224 @default.
• W2602448426 cites W2162741760 @default.
• W2602448426 cites W2163486683 @default.
• W2602448426 cites W2163945848 @default.
• W2602448426 cites W2168997800 @default.
• W2602448426 cites W2315314847 @default.
• W2602448426 cites W2315820302 @default.
• W2602448426 cites W2396683098 @default.
• W2602448426 cites W2489180613 @default.
• W2602448426 cites W2518987895 @default.
• W2602448426 cites W2591717879 @default.
• W2602448426 cites W965220851 @default.
• W2602448426 doi "https://doi.org/10.18632/oncotarget.16491" @default.
• W2602448426 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5438728" @default.
• W2602448426 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28418927" @default.
• W2602448426 hasPublicationYear "2017" @default.
• W2602448426 type Work @default.
• W2602448426 sameAs 2602448426 @default.
• W2602448426 citedByCount "9" @default.
• W2602448426 countsByYear W26024484262018 @default.
• W2602448426 countsByYear W26024484262019 @default.
• W2602448426 countsByYear W26024484262021 @default.
• W2602448426 countsByYear W26024484262022 @default.
• W2602448426 countsByYear W26024484262023 @default.
• W2602448426 crossrefType "journal-article" @default.
• W2602448426 hasAuthorship W2602448426A5000083222 @default.
• W2602448426 hasAuthorship W2602448426A5000731922 @default.
• W2602448426 hasAuthorship W2602448426A5012001115 @default.
• W2602448426 hasAuthorship W2602448426A5039313839 @default.
• W2602448426 hasAuthorship W2602448426A5046632194 @default.
• W2602448426 hasAuthorship W2602448426A5066890510 @default.
• W2602448426 hasAuthorship W2602448426A5091599854 @default.
• W2602448426 hasBestOaLocation W26024484261 @default.
• W2602448426 hasConcept C126322002 @default.
• W2602448426 hasConcept C126838900 @default.
• W2602448426 hasConcept C191897082 @default.
• W2602448426 hasConcept C192562407 @default.
• W2602448426 hasConcept C2776231280 @default.
• W2602448426 hasConcept C2778019345 @default.
• W2602448426 hasConcept C2778455285 @default.
• W2602448426 hasConcept C2779033008 @default.
• W2602448426 hasConcept C2780073493 @default.
• W2602448426 hasConcept C2781362458 @default.
• W2602448426 hasConcept C2989005 @default.
• W2602448426 hasConcept C539932907 @default.
• W2602448426 hasConcept C544519230 @default.
• W2602448426 hasConcept C71924100 @default.
• W2602448426 hasConcept C90924648 @default.
• W2602448426 hasConceptScore W2602448426C126322002 @default.
• W2602448426 hasConceptScore W2602448426C126838900 @default.
• W2602448426 hasConceptScore W2602448426C191897082 @default.
• W2602448426 hasConceptScore W2602448426C192562407 @default.
• W2602448426 hasConceptScore W2602448426C2776231280 @default.
• W2602448426 hasConceptScore W2602448426C2778019345 @default.
• W2602448426 hasConceptScore W2602448426C2778455285 @default.
• W2602448426 hasConceptScore W2602448426C2779033008 @default.
• W2602448426 hasConceptScore W2602448426C2780073493 @default.
• W2602448426 hasConceptScore W2602448426C2781362458 @default.
• W2602448426 hasConceptScore W2602448426C2989005 @default.
• W2602448426 hasConceptScore W2602448426C539932907 @default.
• W2602448426 hasConceptScore W2602448426C544519230 @default.
• W2602448426 hasConceptScore W2602448426C71924100 @default.
• W2602448426 hasConceptScore W2602448426C90924648 @default.
• W2602448426 hasIssue "17" @default.
• W2602448426 hasLocation W26024484261 @default.

• next